| Phase 121 trials |
|
Phase 1
|
NCT06112678 |
Jan → Feb 2024 |
hyperlipidemia, hypertensive disorder |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06088017 |
Oct 2023 → Jan 2024 |
hyperlipidemia |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05698043 |
Jul → Sep 2023 |
hyperlipidemia, combined, 2 |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05749861 |
Apr → Jun 2023 |
hyperlipidemia, combined, 2 |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05634447 |
Dec 2022 → Feb 2023 |
hyperlipidemia |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05549401 |
Sep → Nov 2022 |
— |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05552495 |
Sep → Nov 2022 |
hyperlipidemia, combined, 2 |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05245084 |
Mar → Jun 2022 |
hyperlipidemia, combined, 2 |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05192356 |
Feb → May 2022 |
hyperlipidemia, combined, 2 |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04987970 |
Sep → Nov 2021 |
— |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04883658 |
Jun → Jul 2021 |
— |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04694989 |
Feb → Apr 2021 |
hyperlipidemia, combined, 2 |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04673864 |
Jan → Mar 2021 |
— |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04660370 |
Jan → Feb 2021 |
hyperlipidemia, combined, 2 |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04587206 |
Oct → Dec 2020 |
— |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04258865 |
Mar → Apr 2020 |
hyperlipidemia, hypertensive disorder |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04354987 |
Oct 2019 → Jan 2020 |
hyperlipidemia |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03920579 |
Apr → May 2019 |
hyperlipidemia, hypertensive disorder |
Chong Kun Dang Pharmaceutical |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT03793985 |
Sep → Oct 2018 |
hyperlipidemia |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03726866 |
Aug 2018 → Jan 2019 |
hyperlipidemia, hypertensive disorder |
Chong Kun Dang Pharmaceutical |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT03609606 |
Aug → Sep 2018 |
hyperlipidemia, hypertensive disorder |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|
|
| Phase 32 trials |
|
Phase 3
|
NCT04388215 |
Oct 2019 → Apr 2021 |
essential hypertension, hyperlipidemia |
Chong Kun Dang Pharmaceutical |
Unknown
|
No outcome recorded
|
|
Phase 3
|
NCT04312698 |
Aug 2019 → Jun 2021 |
hyperlipidemia |
Chong Kun Dang Pharmaceutical |
Completed
|
No outcome recorded
|